Roche acquires THP to expand its therapeutic antibody research

Roche today announced that it has acquired Therapeutic Human Polyclonals, Inc. (THP) a privately-owned biotechnology company based in California and Germany.

BASEL, Switzerland | Apr 2, 2007 |
Roche today announced that it has acquired Therapeutic Human Polyclonals, Inc. (THP) a privately-owned biotechnology company based in California and Germany. With its focus on innovative antibody research, THP will be a valuable addition to Roche’s research organization.

"We are delighted about this acquisition as it builds on our strength in therapeutic antibodies," said Jonathan Knowles, Head of Global Research. "THP and its employees will add cutting-edge capabilities and represent an excellent strategic fit with our own R&D organization. We look forward to welcoming the new members to Roche."

Roche paid 56.5 million US dollars in cash to acquire 100% ownership of THP and plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research in Penzberg, Germany.

Modern medical biotechnology uses a wide range of methods to diagnose and treat diseases - from the production of natural products and gene therapy to therapeutic proteins and antibodies. As a company heavily invested in biotechnology and focused on providing added value to patients and healthcare providers, the development of therapeutic proteins and antibodies remains a major emphasis at Roche.

About THP
THP is an emerging biotechnology company focused on research in the field of human antibody technologies. THP has developed a unique transgenic mammalian platform to create human antibodies. The technology will enable the generation of both monoclonal and polyclonal antibody therapeutics with enhanced efficacy.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com.

SOURCE: Roche

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top